Staurenghi G, et al. - This trial was conducted in order to assess the effectiveness and safety of ranibizumab 0.5 mg in patients with macular edema (ME) from any cause except diabetes, retinal vein occlusion, or neovascular age-related macular degeneration. Ranibizumab was superior in best-corrected visual acuity (BCVA) gain to sham for the treatment of ME due to uncommon causes, with a treatment effect (TE) of +2.8 letters vs sham at month 2. High mean BCVA gain was reported (9.6 letters) in the ranibizumab arm at month 12. The TE, however, was variable across the different etiology subgroups, reaching a >1-line TE in BCVA in patients with ME due to inflammatory conditions/post-uveitis or after cataract surgery. It was deduced that ranibizumab was well tolerated, displaying no new safety findings up to month 12.